SG11202104580PA - Liposomal enhanced intra-peritoneal chemotherapy - Google Patents

Liposomal enhanced intra-peritoneal chemotherapy

Info

Publication number
SG11202104580PA
SG11202104580PA SG11202104580PA SG11202104580PA SG11202104580PA SG 11202104580P A SG11202104580P A SG 11202104580PA SG 11202104580P A SG11202104580P A SG 11202104580PA SG 11202104580P A SG11202104580P A SG 11202104580PA SG 11202104580P A SG11202104580P A SG 11202104580PA
Authority
SG
Singapore
Prior art keywords
liposomal
enhanced intra
peritoneal
chemotherapy
peritoneal chemotherapy
Prior art date
Application number
SG11202104580PA
Other languages
English (en)
Inventor
Michael Oefelein
Natarajan Venkatesan
Nitin Swarnakar
Teresa Hong
Guru Betageri
Ramachandran Thirucote
Lining Hutchinson
Original Assignee
Tesorx Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesorx Pharma Llc filed Critical Tesorx Pharma Llc
Publication of SG11202104580PA publication Critical patent/SG11202104580PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202104580PA 2018-11-02 2019-11-04 Liposomal enhanced intra-peritoneal chemotherapy SG11202104580PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862755026P 2018-11-02 2018-11-02
PCT/US2019/059655 WO2020093044A1 (fr) 2018-11-02 2019-11-04 Chimiothérapie intrapéritonéale améliorée liposomale

Publications (1)

Publication Number Publication Date
SG11202104580PA true SG11202104580PA (en) 2021-05-28

Family

ID=70462880

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104580PA SG11202104580PA (en) 2018-11-02 2019-11-04 Liposomal enhanced intra-peritoneal chemotherapy

Country Status (16)

Country Link
US (1) US20220000777A1 (fr)
EP (1) EP3873456A4 (fr)
JP (1) JP2022506612A (fr)
KR (1) KR20210113588A (fr)
CN (1) CN113453667A (fr)
AU (1) AU2019372441A1 (fr)
BR (1) BR112021009940A8 (fr)
CA (1) CA3118530A1 (fr)
CL (1) CL2021001147A1 (fr)
EA (1) EA202191228A1 (fr)
IL (1) IL282860A (fr)
MX (1) MX2021005110A (fr)
PE (1) PE20211468A1 (fr)
PH (1) PH12021551004A1 (fr)
SG (1) SG11202104580PA (fr)
WO (1) WO2020093044A1 (fr)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4128173A (en) * 1975-10-28 1978-12-05 Harrison Lazarus Peritoneal fluid treatment apparatus, package and method
WO1994026253A1 (fr) * 1993-05-19 1994-11-24 The Liposome Company, Inc. Liposome ayant une couche a composants multiples qui contient un agent bioactif en tant que composants integres dans la bicouche
ATE223205T1 (de) * 1994-11-18 2002-09-15 Aphios Corp Verfahren zur herstellung von liposomen, die hydrophobische artzneistoffe enthalten
US20070160656A1 (en) * 2003-05-02 2007-07-12 Dziewiszek Krzysztof J Lipid platinum complexes and methods of use thereof
US20060246124A1 (en) * 2004-11-08 2006-11-02 Pilkiewicz Frank G Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
US9107824B2 (en) * 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056264A2 (fr) * 2005-11-08 2007-05-18 Transave, Inc. Methodes de traitement anticancereux avec des formulations d'un compose de platine a base de lipides d'une haute activite administrees par voie intraperitoneale
WO2009059449A1 (fr) * 2007-11-05 2009-05-14 Celsion Corporation Nouveaux liposomes thermosensibles contenant des agents thérapeutiques
JP2014523444A (ja) * 2011-07-19 2014-09-11 エスティーシー． ユーエヌエム 癌の炎症性環境に基づいて治療用積載物を放出する、腹腔内投与されるナノ担体
BR112014031421A2 (pt) * 2012-06-15 2017-06-27 Brigham & Womens Hospital Inc composições para tratamento de câncer e métodos para produção das mesmas
ES2629294T3 (es) * 2014-07-02 2017-08-08 Paolo Gobbi Frattini S.R.L. Envase flexible con una cámara estéril y hermética para la reconstitución y la administración de sustancias medicinales o nutricionales fluidas instilables en el cuerpo de un paciente
WO2016131006A1 (fr) * 2015-02-13 2016-08-18 Orient Pharma Inc. Compositions et procédés de traitement de tumeur utilisant des nanoparticules
WO2016134066A1 (fr) * 2015-02-17 2016-08-25 Mallinckrodt Llc Formulations de liposomes de docétaxel modifié et utilisations associées
AU2017205337B2 (en) * 2016-01-07 2022-09-08 Tesorx Pharma, Llc Formulations for treating bladder cancer

Also Published As

Publication number Publication date
CA3118530A1 (fr) 2020-05-07
AU2019372441A1 (en) 2021-06-10
EP3873456A4 (fr) 2022-07-27
CN113453667A (zh) 2021-09-28
PE20211468A1 (es) 2021-08-05
BR112021009940A2 (pt) 2021-08-17
PH12021551004A1 (en) 2021-10-04
EP3873456A1 (fr) 2021-09-08
US20220000777A1 (en) 2022-01-06
IL282860A (en) 2021-06-30
EA202191228A1 (ru) 2021-09-24
JP2022506612A (ja) 2022-01-17
WO2020093044A1 (fr) 2020-05-07
KR20210113588A (ko) 2021-09-16
MX2021005110A (es) 2021-08-24
BR112021009940A8 (pt) 2023-03-21
CL2021001147A1 (es) 2021-11-26

Similar Documents

Publication Publication Date Title
CA188236S (en) Headphones
CA185332S (en) Headphone
CA185101S (en) Headphone
CA186640S (en) Headset
CA186642S (en) Headset
AU201717314S (en) Headphone
GB202017534D0 (en) Imprinate 3d
GB201703885D0 (en) Liner firm
GB201812992D0 (en) Liposomes
CA184675S (en) Spa
GB2563327B (en) Vertically-suspended architectural-structure covering
PL3602533T3 (pl) Element świetlny
CA188238S (en) Headphones
GB201800418D0 (en) Headphones
GB201801634D0 (en) #
IL282860A (en) As an enhanced intraperitoneal liposomal therapy
GB2579016B (en) Headphones
GB2585565B (en) Micro-imagery design integration
HUE060479T2 (hu) Polialagút szerkezet
GB201814468D0 (en) Unique headphone design
GB201820652D0 (en) Rotational advantage
ZAF201801185S (en) Insert
ZAA201801025S (en) Maybe design
GB2576916B (en) Polytunnel structure
GB2575634B (en) Polytunnel structure